Basis of Presentation - Additional Information (Detail) $ / shares in Units, $ in Thousands |
12 Months Ended | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Nov. 05, 2019
USD ($)
$ / shares
shares
|
Oct. 29, 2019
USD ($)
$ / shares
shares
|
May 10, 2019
shares
|
May 09, 2019
shares
|
Nov. 09, 2018
USD ($)
|
Dec. 05, 2017
USD ($)
|
Aug. 08, 2017
USD ($)
|
Apr. 18, 2017
USD ($)
|
Dec. 31, 2019
USD ($)
$ / shares
shares
|
Dec. 31, 2018
USD ($)
shares
|
Dec. 31, 2017
USD ($)
|
Oct. 31, 2019
$ / shares
|
Mar. 31, 2019
USD ($)
|
May 10, 2018
shares
|
May 09, 2018
shares
|
|
| Basis Of Presentation [Line Items] | |||||||||||||||
| Reverse stock split ratio | 0.2 | ||||||||||||||
| Description of reverse stock split | At the Company’s annual meeting of stockholders on May 9, 2018 (the “2018 Annual Meeting”), the Company’s stockholders approved an amendment to its Restated Certificate of Incorporation to effect a reverse stock split of its common stock, at a ratio ranging from one-for-five to one-for-fifteen, with the final ratio to be determined by the Company’s board of directors (the “Board”). Immediately after the 2018 Annual Meeting, the Board approved a one-for-five (1:5) reverse stock split of the outstanding shares of the BIOLASE common stock. On May 10, 2018, the Company filed an amendment (the “Fourth Amendment”) to its Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the reverse stock split and to reduce the authorized shares of common stock from 200,000,000 shares to 40,000,000 shares. Except as the context otherwise requires, all current and prior year share numbers (including common stock warrants) and share price amounts (including exercise prices and closing market prices) contained in these audited financial statements and notes thereto reflect the one-for-five reverse stock split. Additionally, in 2018 the Company recorded a reclassification of $0.1 million between common stock and additional paid-in capital, equal to the reduction in par value. | ||||||||||||||
| Common stock, shares authorized | shares | 40,000,000 | 200,000,000 | 40,000,000 | 40,000,000 | 40,000,000 | 200,000,000 | |||||||||
| Reclassification of common stock and additional paid-in capital | $ 100 | ||||||||||||||
| Loss from operations | $ 15,621 | 20,885 | $ 18,038 | ||||||||||||
| Proceeds from equity offering, net of expenses | $ 11,400 | $ 9,500 | $ 10,200 | ||||||||||||
| Borrowings under lines of credit | $ 3,696 | ||||||||||||||
| Shares issued, price per share | $ / shares | $ 0.5750 | ||||||||||||||
| Temporary equity preferred stock, shares issued | shares | 70,000 | 0 | |||||||||||||
| Proceeds from equity offerings | $ 9,171 | $ 21,761 | |||||||||||||
| Net proceeds from issuance of offering and private placement | $ 8,200 | ||||||||||||||
| Working capital | 14,700 | ||||||||||||||
| Cash and cash equivalents, including restricted cash | 6,100 | ||||||||||||||
| Net accounts receivable | $ 8,760 | $ 11,112 | |||||||||||||
| Series E Convertible Preferred Stock | |||||||||||||||
| Basis Of Presentation [Line Items] | |||||||||||||||
| Shares issued, price per share | $ / shares | $ 57.50 | ||||||||||||||
| Temporary equity preferred stock, shares issued | shares | 69,565 | ||||||||||||||
| Convertible preferred stock, shares issued upon conversion | shares | 100 | 100 | |||||||||||||
| Convertible preferred stock, conversion price per share | $ / shares | $ 0.5750 | $ 0.5750 | |||||||||||||
| Underwritten Public Offering | |||||||||||||||
| Basis Of Presentation [Line Items] | |||||||||||||||
| Proceeds from equity offerings | $ 4,200 | ||||||||||||||
| Underwritten Public Offering | Common Stock | |||||||||||||||
| Basis Of Presentation [Line Items] | |||||||||||||||
| Shares issued | shares | 7,820,000 | ||||||||||||||
| Shares issued, price per share | $ / shares | $ 0.5750 | $ 0.5750 | |||||||||||||
| Over-Allotment Option | |||||||||||||||
| Basis Of Presentation [Line Items] | |||||||||||||||
| Shares issued | shares | 1,173,000 | ||||||||||||||
| Shares issued, price per share | $ / shares | $ 0.5750 | ||||||||||||||
| Gross proceeds from issuance of equity | $ 600 | ||||||||||||||
| Private Placement | |||||||||||||||
| Basis Of Presentation [Line Items] | |||||||||||||||
| Gross proceeds from issuance of convertible preferred stock | $ 4,000 | ||||||||||||||
| Private Placement | Series E Convertible Preferred Stock | |||||||||||||||
| Basis Of Presentation [Line Items] | |||||||||||||||
| Shares issued, price per share | $ / shares | $ 57.50 | $ 57.50 | |||||||||||||
| Temporary equity preferred stock, shares issued | shares | 69,565 | 69,565 | 69,565 | ||||||||||||
| Convertible preferred stock, shares issued upon conversion | shares | 69,565 | ||||||||||||||
| Gross proceeds from issuance of convertible preferred stock | $ 4,000 | ||||||||||||||
| SWK Funding LLC | |||||||||||||||
| Basis Of Presentation [Line Items] | |||||||||||||||
| Borrowings under lines of credit | $ 12,500 | $ 12,500 | |||||||||||||
| Line of credit facility, maximum borrowing capacity | $ 12,500 | ||||||||||||||
| Western Alliance | Business Financing Agreement | |||||||||||||||
| Basis Of Presentation [Line Items] | |||||||||||||||
| Line of credit facility, maximum borrowing capacity | $ 6,000 | ||||||||||||||
| Minimum | |||||||||||||||
| Basis Of Presentation [Line Items] | |||||||||||||||
| Reverse stock split ratio | 0.2 | ||||||||||||||
| Maximum | |||||||||||||||
| Basis Of Presentation [Line Items] | |||||||||||||||
| Reverse stock split ratio | 0.067 | ||||||||||||||
| Maximum | Over-Allotment Option | |||||||||||||||
| Basis Of Presentation [Line Items] | |||||||||||||||
| Option to purchase additional common stock granted | shares | 1,173,000 | 1,173,000 | |||||||||||||